Lobbying Filing Details

Total Spending

$1,430,000

Activities

5

Lobbyists

3

Gov't Entities

20

Filing Information
Filing UUID:
76a8aab5-d838-46a9-bde5-1018428e5ce0
Type:
Q3 - 3rd Quarter - Report
Period:
2020 - 3rd Quarter (July 1 - Sep 30)
Date Posted:
October 20, 2020 at 7:44 PM
Income:
$0
Expenses:
$1,430,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Daniel Bachner
Registrant
ABBVIE, INC.

Biopharmaceutical company

Washington, District of Columbia
Client
ABBVIE INC.
District of Columbia, United States of America
Lobbying Activities (5)
Activity 1
Copyright/Patent/Trademark

Patent litigation reform issues and issues related to post-grant proceedings at the PTO
Value of intellectual property

Lobbyists (3)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • BINTA BEARD
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)
Activity 2
Health Issues

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls
H.R.6383, Uterine Fibroid Research and Education Act of 2020
H.R.7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage.
340B drug discount program policy issues
Drug cost and pricing policy issues
Patient affordability issues
Policy proposals relating to clinical trial diversity
Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

Lobbyists (3)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • BINTA BEARD
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)
Activity 3
Medicare/Medicaid

H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions
H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions
S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues
S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing
S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates
S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions
Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First
Executive Order 13938, White House Executive Order on Increasing Drug Importation to Lower Prices for American Patients
Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
Policy Proposals related to Medicare Part D and patient cost-sharing
Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues
Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization
Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in
Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

Lobbyists (3)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • BINTA BEARD
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)
Activity 4
Taxation/Internal Revenue Code

Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation
Draft legislation relating to economic activity in Puerto Rico
International tax issues, including OECD digital taxation work program

Lobbyists (2)
  • STEPHEN SCANGO
  • DANIEL BACHNER
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)
Activity 5
Trade (domestic/foreign)

USMCA and related policy issues
Policy proposals impacting biopharmaceutical supply chain

Lobbyists (2)
  • STEPHEN SCANGO
  • DANIEL BACHNER
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)

Source: LDA.gov, data retrieved November 10, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.